Deliberate self-poisoning with tiagabine: An unusual toxidrome

被引:4
作者
Forbes, Richard A. [2 ]
Kalra, Harish [3 ]
Hackett, L. Peter [5 ]
Daly, Frank F. S. [1 ,4 ]
机构
[1] Univ Western Australia, Royal Perth Hosp, Dept Emergency Med, Perth, WA 6847, Australia
[2] Royal Perth Hosp, Intens Care Unit, Perth, WA, Australia
[3] Royal Perth Hosp, Dept Psychiat, Perth, WA, Australia
[4] Royal Perth Hosp, Dept Clin Toxicol, Perth, WA, Australia
[5] PathWest Lab WA, Dept Clin Pharmacol & Toxicol, Perth, WA, Australia
关键词
adverse effect; poisoning; tiagabine; toxicity;
D O I
10.1111/j.1742-6723.2007.00973.x
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Tiagabine is an anticonvulsant acting by selective inhibition of neuronal and glial gamma-aminobutyric acid uptake, resulting in increased gamma-aminobutyric acid-mediated inhibition in the brain. Few reports in the literature describe the clinical course of severe tiagabine intoxication. A 44-year-old woman presented after deliberate self-poisoning with 100 tiagabine 15 mg tablets (1500 mg; 25 mg/kg). Serum tiagabine level was 4600 mu g/L (1725 mmol/L) at presentation, 20 times levels associated with therapeutic dosing. Intoxication was manifested by profuse vomiting, coma, myoclonus, generalized rigidity, bradycardia, hypertension, hypersalivation and generalized piloerection within 2 h of ingestion. The patient was intubated and management was supportive. Coma lasted until 10 h post-ingestion, but recovery was complicated by severe agitated delirium lasting 12 h. The patient recovered fully within 26 h of ingestion. Tiagabine deliberate self-poisoning was associated with the rapid onset of coma and an unusual toxidrome. Recovery, although complicated by agitated delirium, was complete within 26 h.
引用
收藏
页码:556 / 558
页数:3
相关论文
共 16 条
  • [1] Tiagabine pharmacology in profile
    Brodie, MJ
    [J]. EPILEPSIA, 1995, 36 : S7 - S9
  • [2] Intentional overdose with tiagabine: An unusual clinical presentation
    Cantrell, FL
    Ritter, M
    Himes, E
    [J]. JOURNAL OF EMERGENCY MEDICINE, 2004, 27 (03) : 271 - 272
  • [3] Two cases of nonconvulsive status epilepticus in association with tiagabine therapy
    Ettinger, AB
    Bernal, OG
    Andriola, MR
    Bagchi, S
    Flores, P
    Just, C
    Pitocco, C
    Rooney, T
    Tuominen, J
    Devinsky, O
    [J]. EPILEPSIA, 1999, 40 (08) : 1159 - 1162
  • [4] Fitzek S, 2001, EPILEPTIC DISORD, V3, P147
  • [5] Tiagabine for rage, aggression, and anxiety
    Hoffman, DA
    [J]. JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2005, 17 (02) : 252 - 252
  • [6] Tiagabine-induced absence status in idiopathic generalized epilepsy
    Knake, S
    Hamer, HM
    Schomburg, U
    Oertel, WH
    Rosenow, F
    [J]. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 1999, 8 (05): : 314 - 317
  • [7] Tiagabine
    Leach, JP
    Brodie, MJ
    [J]. LANCET, 1998, 351 (9097) : 203 - 207
  • [8] DELIBERATE OVERDOSE WITH THE NOVEL ANTICONVULSANT TIAGABINE
    LEACH, JP
    STOLAREK, I
    BRODIE, MJ
    [J]. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 1995, 4 (02): : 155 - 157
  • [9] Safety of tiagabine: summary of 53 trials
    Leppik, IE
    Gram, L
    Deaton, R
    Sommerville, KW
    [J]. EPILEPSY RESEARCH, 1999, 33 (2-3) : 235 - 246
  • [10] Tiagabine: The safety landscape
    Leppik, IE
    [J]. EPILEPSIA, 1995, 36 : S10 - S13